Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nuttn going on here...neat company lots of promise but still a very risky investment....good luck
Leading Chemical Dependency Recovery Center Successfully Begins Treating Patients With CITA Biomedical's Innovative Treatments for Alcohol, Cocaine, And Crack Dependence
LCM Chemical Dependency Recovery Center Treats First DNA for Addictions Patient for Alcoholism
BEVERLY HILLS, Calif., Dec. 16 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of addiction dependency, today announced that Little Company of Mary (LCM) Chemical Dependency Recovery Center in San Pedro, California successfully began treating patients using CITA's Detoxification and NeuroAdaptation (DNA) for Addictions family of treatments. The first patient was treated for alcoholism with CITA's DNA for Alcohol. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
The patient, a 55-year-old male who had been dependant on alcohol for 43 years was treated with DNA for Alcohol. The patient was consuming an average of one quart of alcohol daily. "I've tried several programs including Betty Ford, St. Joseph's, and I've been in and out of AA," said the patient. "The DNA for Alcohol treatment is miraculous! I continue to have no desire to drink and can't even remember what alcohol tastes like." The treatment was administered to the patient for less than an hour daily over two consecutive days and he experienced no withdrawal symptoms.
DNA for Addictions establishes a new treatment regimen in the fight against drug addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating disease.
DNA for Addictions patients experience a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.
"Now that we have multiple centers serving California we're ready to open centers across the United States," said Joseph Dunn, president and CEO of CITA Biomedical. "The patient testimonial from LCM Chemical Dependency Recovery Center is similar to comments from all our patients treated so far. Treating both the physical and psychological components of addiction are key to DNA for Addictions' success and what sets DNA apart from any other treatments."
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
About Little Company of Mary Chemical Dependency Recovery Center
Little Company of Mary Chemical Dependency Recovery Center in San Pedro is a non-profit alcohol and drug rehabilitation center affiliated with Little Company of Mary -- an integrated regional health care system serving the South Bay and Harbor communities of Los Angeles. For more than 25 years, the center has provided a full range of rehabilitative services at our facility, located adjacent to San Pedro Peninsula Hospital.
UROD is a registered trademark of CITA Biomedical, Inc.
Contacts:
Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
jryon@citabio.com Visit: www.cita1.com
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon, Investor Relations of CITA Biomedical, Inc.,
+1-310-550-4971, jryon@citabio.com ; or Treatment Information,
+1-888-400-2482
Web site: http://www.citabio.com
http://www.cita1.com
CITA Biomedical Begins Executive Search
BEVERLY HILLS, Calif., Dec. 13 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (CITA) (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the search has begun for a new president and chief financial officer (CFO) to replace the departing president, Steven J. Rutlen and CFO, John Peters.
Both Mr. Rutlen and Mr. Peters are leaving CITA to pursue opportunities that are more inline with their interests and goals. CITA is aggressively working on recruiting top executives with experience in building companies and managing them through rapid growth. In the interim Joseph Dunn, chairman and CEO of CITA Biomedical will serve as president and CFO.
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
UROD is a registered trademark of CITA Biomedical, Inc.
The information contained in this press release includes forward-looking statements. Forward-looking statements include declarations concerning plans, objectives, goals, strategies, future events and/or performance, and underlying assumptions and other statements which are other than statements of historical facts. Forward-looking statements usually contain the words "estimate," "anticipate," "believe," "expect" and other similar expressions that involve risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company's status as a start-up enterprise with uncertain profitability, its need for significant capital, limited facilities, competition, uncertainty as to market acceptance of its services, and the protection of its intellectual property. The Company's actual results could differ materially from those expressed or implied in any forward-looking statements.
Contacts:
Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
jryon@citabio.com Visit: www.citatreatment.com
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971,
jryon@citabio.com, or CITA Biomedical Treatment Information, +1-888-400-2482
Web site: http://www.citabio.com
http://www.citatreatment.com
Until CandyMan returns to update this board, please feel free to enjoy continuing support of this subject at:
http://www.investorshub.com/boards/board.asp?board_id=1243
John
.
Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!
CITA Bio refers to a George Koob, PhD on their website.
The guy seems to have some credibility: http://www.ndsn.org/FEB96/TREATMEN.html
Cocaine Immunization Successfully Tested in Rats TREATMENT
February 1996
On December 14, the National Institute on Drug Abuse (NIDA) announced that researchers funded by NIDA had successfully tested a substance that acts to immunize rats from the effects of cocaine (John A. Bowersox, "New Strategy Would Neutralize Cocaine in the Bloodstream," NIDA Notes, September/October 1995, p. 1, "Research Finds Immunization Can Block the Effects of Cocaine," Substance Abuse Letter, January 2, 1996, p. 1).
Researchers, in a process called "active immunization," injected rats with cocaine linked to a large protein that causes the body to produce antibodies. These antibodies recognize and chemically hook on to cocaine molecules, preventing them from producing an effect. Over long periods of time, the cocaine drops off the protein and is processed by the body.
The researchers found that rats with the antibodies had 70 percent less cocaine in their brains than non-immunized rats when the two populations were administered equal amounts of cocaine. Immunized rats also showed substantially less physical effect from cocaine.
Researchers Kim Janda, PhD, Rocio Carrera, MA, and George Koob, PhD of The Scripps Research Institute said the immunization method has an advantage over other cocaine addiction treatment programs because antibodies remain in the blood for a long period of time. The vaccine also has the advantage of not affecting brain chemistry as other cocaine treatments do. The vaccine may also prove useful in treating cocaine overdoses.
Dr. Alan Leshner, director of the National Institute on Drug Abuse (NIDA), said that development of a cocaine treatment or prevention medication is "this country's most important need in the fight against drug abuse and addiction."
Researchers cautioned that there are a number of issues to be studied before human clinical trials could begin: how long the vaccine remains in the bloodstream, the effect of "booster" shots, and the possibility that cocaine addicts will take more cocaine to overcome the effects of the vaccine.
Dr. Charles Schuster, former director of NIDA (1986-92), who is now Director of the Clinical Program for Substance Abuse at Wayne State University, tested an active immunization process for heroin in monkeys in the 1970s at the University of Chicago. Immunized monkeys stopped self-administering heroin although they would self-administer other drugs. Further, when the dose of heroin was increased 16-fold, the antibody pool became saturated and the monkey began to self-administer heroin again.
An even more important problem with immunization, Schuster told NewsBriefs, is that people immunized to the effects of one drug may substitute another drug to produce the same effect. Producing immunizations for all drugs would be an impossible task.
"We can't look at this as a magic bullet to substance abuse," Schuster said. "It will help individuals stop using cocaine, but we will need other interventions to prevent them from switching to other stimulant drugs such as amphetamines."
The jury is still out - DYODD..............!!!
John
Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!
CITA Biomedical's Proprietary Program to End Cocaine Dependence Used To Successfully Treat First U.S. Patient for Cocaine Addiction
Patient Had No Withdrawal Symptoms and After Treatment No Cravings for Alcohol or Cocaine
BEVERLY HILLS, Calif., July 16 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the first U.S. Detoxification and NeuroAdaptation (DNA) for Cocaine patient was successfully treated for cocaine dependence. DNA for Cocaine is a part of a family of treatments called DNA for Addictions. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Cocaine, DNA for Alcohol and Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO )
The patient, a 35-year-old male first used marijuana and alcohol at age 15. At age 17 he was free-basing which eventually turned into a $2000 a week cocaine and crack cocaine habit, including the consumption of a fifth of alcohol or two six-packs of beer daily plus marijuana use. "I've probably tried 20 or more programs including residential, in-patient, out-patient, AA, and NA," said the patient. "There are a lot of advantages to DNA but the biggest advantage is that you don't even think of alcohol or cocaine! You don't crave it. You just don't think about it! I've tried to quit in the past but it never worked out until now." The treatment was administered to the patient for less than an hour daily over three consecutive days. The patient experienced no symptoms of withdrawal.
DNA for Cocaine establishes a new treatment regimen in the fight against cocaine addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Cocaine addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of cocaine addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating condition.
The patients that were treated in Europe last year experienced a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating cocaine addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.
"We are pleased to begin another proven safe and effective DNA for addictions treatment in the U.S. We anticipate that this patient will be the first of thousands that we will treat for alcohol and cocaine dependence in the coming year," said Joseph Dunn, president and CEO of CITA Biomedical. "DNA took years to develop and continues to be extremely successful in Europe with our CITA affiliate. CITA is pleased to finally help address the devastation to society caused by cocaine and crack cocaine dependence."
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently announced a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat cocaine, cocaine, and poly-drug addictions. To date CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
UROD is a registered trademark of CITA Biomedical, Inc.
For further information please contact: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971, jryon@citabio.com; or Laurel Moody of Vision Corporate Consulting, +1-212-446-6109, laurel@visioncc.net, for CITA Biomedical, Inc.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X01168831
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971,
jryon@citabio.com; or Laurel Moody of Vision Corporate Consulting,
+1-212-446-6109, laurel@visioncc.net, for CITA Biomedical, Inc.
Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO
PRN Photo Desk, 888-776-6555 or 212-782-2840
Web site: http://www.citabio.com
First U.S. Patient Successfully Treated for Alcoholism with CITA Biomedical's Innovative Program to End Alcohol Dependence
Treated in Just Two Days, Patient Suffered No Withdrawal Symptoms and After Treatment had No Cravings for Alcohol
Beverly Hills, Calif., July 9, 2002 - CITA Biomedical, Inc. (OTCBB:DTOX) a growing leader in the treatment of substance dependency, today announced that the first U.S. Detoxification and Neuro-Adaptation (DNA) for Alcohol patient was successfully treated for alcohol dependence. DNA for Alcohol is a part of a family of treatments called DNA for Addictions.
The patient, a 62-year-old male who had been dependant on alcohol for over 40 years was treated with DNA for Alcohol. The patient was consuming an average of 1.5 liters of gin, brandy, and beer a day. The treatment was administered to the patient over two consecutive days where the patient experienced no symptoms of withdrawal. After treatment the patient said he felt an overwhelming sense of happiness, had no cravings for alcohol, and mental clarity that he had not felt for years.
DNA for Alcohol establishes a new treatment regimen in the fight against alcoholism, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Alcoholism causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of alcoholism has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating condition.
The patients that were treated in Europe last year experienced a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating alcoholism. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment’s completion.
"We are pleased to bring the proven safe and effective DNA for Addictions treatments to the U.S. Years in development and extremely successful with our CITA affiliate in Europe, we feel DNA for Addictions will revolutionize the treatment of substance dependence worldwide.” said Joseph Dunn, president and CEO of CITA Biomedical. We anticipate that this patient will be the first of thousands that we will treat for alcohol dependence in the coming year. Our mission is to make the transition from substance dependence to independence as smooth and humane as possible and with DNA for Addictions we’ve done that.”
The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently announced a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, and poly-drug addictions. To date, CITA has grown it’s business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance it’s corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit http://www.citabio.com
UROD is a registered trademark of CITA Biomedical, Inc.
Contacts:
CITA Biomedical, Inc.
Judy Ryon, 310-550-4971 jryon@citabio.com
Vision Corporate Consulting
Laurel Moody, 212-446-6109 laurel@visioncc.net
.
Cita Bio PRs..: http://www.citabio.com/news.html
John
Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!
Cita Bio website: http://www.citabio.com/
John
Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11
|
Created
|
07/25/00
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |